Trial Profile
The effect of canakinumab adjunctive treatment on symptoms and cognition in people with schizophrenia displaying elevated peripheral inflammatory markers
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 22 Oct 2018
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary)
- Indications Schizoaffective disorder; Schizophrenia
- Focus Therapeutic Use
- Acronyms CATS
- 16 Oct 2018 Status changed from recruiting to completed.
- 11 May 2016 Status changed from not yet recruiting to recruiting.
- 02 Jul 2015 New trial record